Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Thyroid Gland Hurthle Cell Carcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Thyroid Gland Carcinoma (337)

Thyroid Gland Anaplastic Carcinoma (60)

Thyroid Gland Medullary Carcinoma (58)

Thyroid Gland Papillary Carcinoma (53)

Thyroid Gland Follicular Carcinoma (25)

Thyroid Gland Carcinoma (337)

Thyroid Gland Anaplastic Carcinoma (60)

Thyroid Gland Medullary Carcinoma (58)

Thyroid Gland Papillary Carcinoma (53)

Thyroid Gland Follicular Carcinoma (25)

›

No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
TMB-H	Thyroid Gland Hurthle Cell Carcinoma	TMB-H	Thyroid Gland Hurthle Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
RET fusion	Thyroid Gland Hurthle Cell Carcinoma	RET fusion	Thyroid Gland Hurthle Cell Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Thyroid Gland Hurthle Cell Carcinoma	RET fusion	Thyroid Gland Hurthle Cell Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK3 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK3 fusion	Thyroid Gland Hurthle Cell Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2